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Introduction: Management of type 2 diabetes is aimed at reducing disease-
related complications and improving long-term outcomes. Inhibition of 
dipeptidyl peptidase-4 (DPP-4) activity by sitagliptin has been shown to 
improve glycaemic control in patients with type 2 diabetes Mellitus 
(T2DM) by prolonging the actions of incretin hormones, but the real impact 
of low-dose sitagliptin treatment on cardiometabolic risk factors and 
pancreatic lesions is almost unknown. This study aimed to evaluate the 
effects of low doses of sitagliptin on cardiovascular risk factors and 
histological pancreas parameters in Zucker Diabetic Fatty rats (ZDF (fa/fa), 
an animal model of T2DM. 
Materials and Methods: Twenty-week-old diabetic obese (fa/fa) ZDF male 
rats were treated with vehicle or sitagliptin (10 mg/kg BW/day) for 6 weeks 
(n=8 each). The following parameters were assessed: glycaemia, HbA1c, 
insulin, lipid profile; blood pressure. Pancreas specimens for 
histopathological examination were stained with haematoxylin-eosin and 
periodic-acid-Shiff and examined under light microscopy. Endocrine and 
exocrine pancreas were evaluated semiquantitatively for inflammatory 
infiltrate, fibrosis, vacuolisation and congestion, and scored from 0 (absent) 
to 3 (severe and extensive damage). 
Results: Sitagliptin in diabetic obese ZDF rats exerted a positive effect on 
dysglycaemia and dyslipidaemia, and prevented increases in blood pressure. 
Endocrine and exocrine pancreas displayed a reduction/improvement in 
fibrosis severity, inflammatory infiltrate, intra-islet vacuolation, and 
congestion with respect to vehicle-treated diabetic rats. 
Conclusion: Simultaneous and sustainable improvement in the glycaemic 
profile and in pancreatic histopathological lesions supports the favorable 
cardiovascular risk profile and may prove beneficial in reducing the long-
term complications of T2DM.  
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